Skip to main content
SpringerLink
Log in

On Chronic Cough Diagnosis, Classification, and Treatment

  • LETTER TO THE EDITOR
  • Published:
Lung Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dicpinigaitis PV (2021) Coming soon: the first-ever drug(s) for refractory chronic cough. Lung 199(2):83–84

    Article  Google Scholar 

  2. Morice AH, Birring SS, Smith JA, McGarvey LP, Schelfhout J, Martin Nguyen A, Xu ZJ, Wu WC, Muccino DR, Sher MR (2021) Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant. Lung 199(2):121–129

    Article  CAS  Google Scholar 

  3. Park J-s, Burton L, Van der Wall H, Falk GL (2021) Modified reflux scintigraphy detects pulmonary microaspiration in severe gastro-esophageal and laryngopharyngeal reflux disease. Lung 199(2):139–145

    Article  Google Scholar 

  4. Morice AH, Faruqi S, Wright CE, Thompson R, Bland JM (2011) Cough hypersensitivity syndrome: a distinct clinical entity. Lung 189(1):73–79

    Article  CAS  Google Scholar 

  5. McGarvey L, Birring S, Morice A, Dicpinigaitis P, Pavord I, Schelfhout J, Martin Nguyen A, Li Q, Tzontcheva A, Iskold B, Green S, La Rosa C, Muccino D, Smith J (2020) Late breaking abstract—two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2). Eur Respir J 56(suppl 64):3800

    Google Scholar 

  6. Morice A, Birring S, Dicpinigaitis P, McGarvey L, Pavord I, Smith J, La Rosa C, Li Q, Martin Nguyen A, Schelfhout J, Tzontcheva A, Muccino D (2021) Cough triggers and symptoms among patients with refractory or unexplained chronic cough in two phase 3 trials of the P2X3 receptor antagonist gefapixant (COUGH-1 and COUGH-2). J Allergy Clin Immunol 147(2):AB61

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Clinical Sciences, University of Hull, Cottingham, UK

    Alyn Hugh Morice

Authors
  1. Alyn Hugh Morice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alyn Hugh Morice.

Ethics declarations

Conflict of interest

AM has received consulting fees from Bayer, Bellus, Boehringer Ingelheim, Merck, Pfizer, and Proctor & Gamble, Shionogi lecture fees from Boehringer Ingelheim and AstraZeneca, and grant support from Proctor & Gamble, Merck, Afferent, and Infirst.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morice, A.H. On Chronic Cough Diagnosis, Classification, and Treatment. Lung 199, 433–434 (2021). https://doi.org/10.1007/s00408-021-00452-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-021-00452-8

Search

Navigation